Stay updated on Nivolumab in AML Remission at High Risk Clinical Trial

Sign up to get notified when there's something new on the Nivolumab in AML Remission at High Risk Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab in AML Remission at High Risk Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    No Change Detected
  3. Check
    17 days ago
    Change Detected
    Summary
    Revision: v3.4.2 was added and older revision notices (v3.4.1) were removed, along with a government funding status notice; these are site housekeeping changes that do not alter the study content. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.5%
    Check dated 2026-02-11T11:47:51.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    Administrative updates were added: a government funding notice and revision to v3.4.1 replacing v3.4.0, which do not affect core trial content or data. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.5%
    Check dated 2026-02-04T06:38:54.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    The updates are minor UI and metadata changes (Show glossary; Last Update Submitted that Met QC Criteria; No FEAR Act Data; Revision: v3.4.0) that do not alter the core study content, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-28T04:36:37.000Z thumbnail image
  6. Check
    45 days ago
    Change Detected
    Summary
    The page shows a revision update from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-14T02:36:42.000Z thumbnail image
  7. Check
    66 days ago
    Change Detected
    Summary
    The updates include adding a 'Locations' and 'Texas' label and removing the 'Texas Locations' header, and removing the HHS Vulnerability Disclosure footer link. These are minor labeling and navigation changes that do not affect study data, eligibility, or user actions.
    Difference
    0.2%
    Check dated 2025-12-23T13:51:43.000Z thumbnail image
  8. Check
    88 days ago
    Change Detected
    Summary
    Revision notice updated from v3.3.1 to v3.3.2 across the page footer, indicating a minor site update that does not affect study content or usability. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-12-01T18:51:59.000Z thumbnail image

Stay in the know with updates to Nivolumab in AML Remission at High Risk Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab in AML Remission at High Risk Clinical Trial page.